Noopept (omberacetam; GVS-111) vs semax

Noopept (omberacetam; GVS-111) (B-tier) vs semax (B-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

Noopept (omberacetam; GVS-111) · tier B

omberacetam, a small-molecule cognitive drug sold as a registered 10 mg oral tablet in Russia. the cited human signal comes from one small patient comparison, not a healthy-user trial.

Noopept has a current Russian drug registration and a limited patient signal. It does not have placebo-controlled evidence of cognitive enhancement in healthy people, and sampled US supplements did not reliably define the exposure.

53 patients enrolled in the main active-comparator study · half-life 22.05 plus or minus 14.37 minutes in a sparsely reported human conference abstract · focus

semax · tier B

russian nootropic. approved there, not here. for focus, stroke recovery, and cognitive decline. real mechanism, thin US trials.

Russian nootropic. approved there since the 1990s. BDNF upregulation within 30 minutes of an intranasal dose, effect persists 24+ hours.

Russia '82 stroke registry · half-life minutes in plasma; effects persist for hours due to CNS penetration and BDNF induction cascade · focus

at a glance

• Noopept (omberacetam; GVS-111): tier B · 53 patients enrolled in the main active-comparator study
• semax: tier B · Russia '82 stroke registry

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.